RELEVANCE OF SOME SERUM BIOMARKERS (E CADHERIN, GAGS MDA IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA

This study aimed to estimate the pretreatment serum levels of SVE-Cadherin, glycosaminoglycams (GAGs) and malondialdehyde (MDA) in order to evaluate their prognostic significance and their role in monitoring tumor response and overall-survival in Non Hodgkin lymphoma (DLCL) patients. Also the work aimed to investigate the relationship between levels of these biochemical markers with LDH level, ESR and tumor stage. For this purpose pretreatment serum levels of these biochemical markers were evaluated in 40 newly diagnosed patients with non-Hodgkin lymphoma (Diffuse large cell type) and studied in relation to expression in healthy control. Our results revealed that serum levels of SVE-Cadherin, GAGs and MDA increased significantly (P 0.05) in NHL patients (DLCL) as compared to control, no significant relation between these parameters and ESR, LDH. However, higher level of SVE-Cadherin was found in stage II, III of the disease as compared to stage IV disease but with no statistical significance. Regarding response to therapy, only MDA showed a significant relation with response of the patient to treatment. Concerning overall survival there is no statistical significance was found between these parameters OS in NHL patients. Elevated levels of SVE-Cadherin, GAGs and MDA in NHL patients indicate that they may have a role in the pathogenesis of the disease. High level of MDA may be used as a predictor for tumor response to systemic chemotherapy. Low level of SVE-Cadherin in stage IV participates in the invasiveness and metastasis of the disease.